Because of the multiple engagements of TFIIH, different mutations in a single TFIIH subunit can trigger any of the clinical entities described above (TTD, XP and CS), depending on the mutation’s effect on, respectively, gene transcription, GG-NER, or TC-NER (or its combined effects). This evidence concerns the gene ERCC3 and xeroderma pigmentosum.